UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000232
Receipt number R000000234
Scientific Title A randomized, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day)
Date of disclosure of the study information 2006/12/01
Last modified on 2007/03/20 17:13:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day)

Acronym

Preventive effect on acute exacerbation of chronic obstructive pulmonary disease with Carbocisteine (PEACE Study)

Scientific Title

A randomized, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day)

Scientific Title:Acronym

Preventive effect on acute exacerbation of chronic obstructive pulmonary disease with Carbocisteine (PEACE Study)

Region

Japan


Condition

Condition

COPD

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the preventive effect of acute exacerbation in COPD patient (StageII-IV) with Carbocisteine (1500mg/day) for 13 months treatment

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequency of exacerbations

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Carbocisteine treatment group
1500mg/day (13 months)

Interventions/Control_2

Treatment group without mucolytic agents including Carbocisteine (13 months)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Stable COPD patient (Stage II-IV)
2. Between 40 and 80 years
3. Out-patient
4. Written informed consent
5. At least 2 exacerbations in the previous 2 years

Key exclusion criteria

1. Intolerance for Carbocisteine
2. Use of mucolytic agents within one month prior to beginning of the study
3. Use of antibiotics at the beginning of the study
4. Bronchiectasis, pneumonia, interstitial lung disease, tuberculosis
5. Carcinoma
6. Previous lung transplant or lung volume reduction surgery
7. Pregnant or breastfeeding
8. Attendance in the other study within 3 months prior to the beginning of the study
9. Underlying severe disease

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshinosuke Fukuchi

Organization

Juntendo University, School of Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

2-1-1 Hongo, Bunkyo-Ku, Tokyo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Juntendo University, School of Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

2-1-1 Hongo, Bunkyo-Ku, Tokyo

TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Respiratory Medicine Juntendo University, School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2006 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2005 Year 04 Month 19 Day

Date of IRB


Anticipated trial start date

2005 Year 06 Month 01 Day

Last follow-up date

2006 Year 10 Month 01 Day

Date of closure to data entry

2006 Year 10 Month 01 Day

Date trial data considered complete

2006 Year 10 Month 01 Day

Date analysis concluded

2006 Year 11 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 09 Month 13 Day

Last modified on

2007 Year 03 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000234


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name